The assay outcomes demonstrated that silencing AGPAT4 via siRNA2 transfection significantly impeded the proliferation of ESCs, as evidenced by the comparative analysis with the NC and BC groups (p < 0.05, Fig. 5B). This evidence concerns the gene AGPAT4 and breast cancer.